Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Receptagen Ltd. -- Ignore unavailable to you. Want to Upgrade?

To: TERENCE DALY who wrote (117)	7/19/1998 2:18:00 PM
From: Russell J. Gilbert	Read Replies (1) \| Respond to of 203

Terence, As you are probably aware, I try to keep on top of the RCG situation and pass along what I know to other shareholders. I think this deal will be beneficial to shareholders especially in light of current circumstances. It certainly is much better than the SCITECH situation. Remember Generex? Well, take a look at their stock price today. Last time I looked it was around $8.00/U.S. share. If I understand the GRN situation correctly, although it is a different kind of company, the majors involved are impressive to say the least. All this was published in the proxy circular. What we need to find out however is what GRN plans are post merger. Looking at other CRO's, if GRN performs even on the low end, you are looking at a post consolidation price of $5.00-$12.00 share U.S.. That equals to .25 - .60 share pre consolidation. Terence, if you would be kind enough to call GRN and find out some of their post merger plans, it would be much appreciated. It might even get some of the other RCG shareholders out of the woodwork and post here. Looking forward to seeing what you find out. PS: I also post on STOCKHOUSE. Go to the forums section and type in RCG.